Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

DOI10.1007/S00362-016-0790-7zbMath1398.62351OpenAlexW2467367917WikidataQ54987395 ScholiaQ54987395MaRDI QIDQ725696

Graham M. Wheeler

Publication date: 2 August 2018

Published in: Statistical Papers (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1007/s00362-016-0790-7

zbMATH Keywords

coherenceadaptive designsBayesian statisticsmaximum tolerated dosephase I trialsdose-escalation

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50) Sequential statistical design (62L05)

Related Items (1)

A continual reassessment method without undue risk of toxicity

Uses Software

• elicit-normlin

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• A Bayesian approach for the estimation of probability distributions under finite sample space
• Bayesian and robust Bayesian analysis under a general class of balanced loss functions
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Unifying CRM and EWOC designs for phase I cancer clinical trials
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Basic concepts of multiple tests -- a survey
• Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
• Design and Analysis of Phase I Clinical Trials
• Coherence principles in dose-finding studies
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

This page was built for publication: Incoherent dose-escalation in phase I trials using the escalation with overdose control approach